Xtant Medical Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98420P3082
USD
0.61
0.01 (2.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Xtant Medical Holdings, Inc. stock-summary
stock-summary
Xtant Medical Holdings, Inc.
Pharmaceuticals & Biotechnology
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.
Company Coordinates stock-summary
Company Details
664 Cruiser Ln , BELGRADE MT : 59714-9719
stock-summary
Tel: 1 406 38804801 877 8891972
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (2.14%)

Foreign Institutions

Held by 8 Foreign Institutions (0.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Sean Browne
President, Chief Executive Officer, Director
Mr. John Bakewell
Director
Mr. Michael Eggenberg
Director
Mr. Robert McNamara
Director
Mr. Jeffrey Peters
Director
Mr. Matthew Rizzo
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
35 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 80 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.58

stock-summary
Return on Equity

-9.45%

stock-summary
Price to Book

1.65